Special Reports
In-depth commissioned reports on the most clinically and commercially significant topics in life science. Built for biopharma professionals, clinicians, CROs, and investors.
Published Reports
GLP-1 and Beyond: The Oral Revolution in Obesity Medicine
How oral semaglutide and new dual agonists are reshaping the largest therapy area in pharma
Cracking the Undruggable: KRAS Inhibitors Rewrite Solid Tumor Oncology
From G12C to pan-RAS: the mutation-by-mutation guide to the KRAS revolution
MASH 2026: Building on the First-Ever Approved Therapy
Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility
EGFR-Mutated Lung Cancer: A New Survival Benchmark
Amivantamab plus lazertinib vs osimertinib: a survival benchmark four years in the making
HFpEF Finally Has Answers: Finerenone, SGLT2s, and What Comes Next
The largest unmet need in cardiology finally has a multi-drug evidence base
Multiple Myeloma: On the Threshold of Cure
Four bispecific antibodies, two CAR-T therapies, and a treatment landscape that moves monthly
Antibody-Drug Conjugates: The Platform That Ate Oncology
From 1 approval to 15: how the ADC platform reshaped every solid tumor type
Autoimmune Disease 2026: JAK Inhibitors Expand, EULAR Rewrites the Playbook
12 FDA-approved JAK inhibitors, updated EULAR guidelines, and the TYK2 era beginning
Breast Cancer 2026: ADCs, CDK4/6 Combinations, and the Endocrine Therapy Reset
HER2-low, HER2-ultralow, and the ADC cascade that changed how tumors are classified
